Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 73.91% from the stock’s previous close.

GMAB has been the subject of several other reports. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and an average target price of $48.50.

Genmab A/S Trading Up 3.8 %

Genmab A/S stock opened at $28.75 on Tuesday. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.72. The stock has a market cap of $19.01 billion, a P/E ratio of 29.95, a price-to-earnings-growth ratio of 2.05 and a beta of 0.99. The stock has a 50 day moving average of $29.41 and a 200-day moving average of $29.93.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The firm had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. As a group, equities analysts predict that Genmab A/S will post 1.06 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Wealth LLC raised its position in shares of Genmab A/S by 50.7% during the 4th quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock worth $3,820,000 after purchasing an additional 40,382 shares during the period. Keybank National Association OH acquired a new stake in Genmab A/S in the 3rd quarter valued at approximately $1,154,000. Knights of Columbus Asset Advisors LLC increased its position in Genmab A/S by 16.8% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock valued at $201,000 after acquiring an additional 822 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Genmab A/S by 350.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after acquiring an additional 3,770 shares during the period. Finally, Northern Trust Corp increased its position in Genmab A/S by 83.3% in the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after acquiring an additional 254,042 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.